Provided by Tiger Trade Technology Pte. Ltd.

Chemomab Therapeutics Ltd.

2.59
+0.290012.61%
Post-market: 2.52-0.0700-2.70%19:53 EDT
Volume:421.31K
Turnover:1.06M
Market Cap:18.98M
PE:-2.57
High:2.65
Open:2.36
Low:2.32
Close:2.30
52wk High:3.86
52wk Low:1.35
Shares:7.33M
Float Shares:6.14M
Volume Ratio:3.93
T/O Rate:6.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0070
EPS(LYR):-1.4103
ROE:-82.17%
ROA:-46.27%
PB:2.19
PE(LYR):-1.84

Loading ...

Press Release: Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
May 14

Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
May 11

Chemomab Therapeutics holds annual shareholders meeting, re-elects directors

Reuters
·
May 07

Chemomab Therapeutics director Neil Cohen files initial beneficial ownership statement

Reuters
·
Apr 11

Chemomab Therapeutics files Form 3 as director Nissim Darvish reports holdings

Reuters
·
Apr 11

Chemomab files Form 3 for CFO Fatal Sigal’s initial beneficial ownership stake

Reuters
·
Apr 11

Chemomab files Form 3 for Chief Development Officer John Lawler

Reuters
·
Apr 11

Chemomab files initial beneficial ownership statement for director Claude Nicaise

Reuters
·
Apr 01

Chemomab files Form 3 for director Jill Quigley’s beneficial ownership statement

Reuters
·
Apr 01

Maxim Group Remains a Buy on Chemomab Therapeutics (CMMB)

TIPRANKS
·
Mar 20

Chemomab FY 2025 net loss fell 35.5% to USD 9 million

Reuters
·
Mar 19

Chemomab Therapeutics: Evaluating Additional Therapeutic Indications Where Nebokitug Has Generated Robust Preclinical Efficacy Signals

THOMSON REUTERS
·
Mar 19

Chemomab Therapeutics Q4 Operating Expenses USD 1.974 Million

THOMSON REUTERS
·
Mar 19

Press Release: Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Dow Jones
·
Mar 19

Chemomab Therapeutics Ltd expected to post a loss of 31 cents a share - Earnings Preview

Reuters
·
Feb 27